2 vials Save $73.75

CJC-1295 + Ipamorelin 10mg + Tesamorelin 10mg Bundle

CJC-1295 No DAC + Ipamorelin 10mg

2-component research blend

$168.74

Tesamorelin 10mg

44-residue peptide

$199.99

Research bundle · 2 vials

CJC-1295 + Ipamorelin 10mg + Tesamorelin 10mg Bundle

USA Made, ≥99% Purity Per Compound

Separate retail vials: CJC-1295 No DAC + Ipamorelin 10mg (5mg + 5mg); Tesamorelin 10mg
USA manufactured in a Certified GMP California and Arizona laboratory.
≥99% purity target per compound with third-party HPLC, mass spectrometry, and batch-specific COAs

Combined retail value$368.73

Bundle saving−$73.75

$294.98 $368.73 Save $73.75

Each vial ships in its original retail format with its own batch COA

Dispatched from a US warehouse within 48 hours, tracked

Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

Disclaimer

For research purposes only. Not intended for human consumption, medical use, diagnosis, treatment, or prevention of disease.

Per-compound specifications

2 vials

Nothing in this bundle is co-formulated. Each vial keeps its own identity, purity target, and certificate, and is specified separately below.

Vial 01

CJC-1295 No DAC + Ipamorelin 10mg

Sequences

CJC: Y-(D-Ala)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2; Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2

CAS: CJC-1295 No DAC: 446036-97-1; Ipamorelin: 170851-70-4
Molecular mass: CJC-1295 No DAC: 3,367.95 g/mol; Ipamorelin: 711.9 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Vial 02

Tesamorelin 10mg

Sequence

N-terminal trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL

CAS: 218949-48-5
Molecular mass: 5,136 g/mol
Purity target: ≥99%
Form: Lyophilized Powder

Form: 2 Separate Lyophilized Powders
Purity target: ≥99% per compound (3rd-Party HPLC Tested)
Origin: All Included Products: Synthesized, Formulated & Packaged in CA/AZ, USA
Storage: Store at -20°C (Freeze) or 2–8°C (Refrigerated) protected from light

What is the CJC-1295, Ipamorelin, and Tesamorelin Research Bundle?

This two-vial bundle includes a 10mg CJC-1295 No DAC + Ipamorelin blend and a separate Tesamorelin 10mg vial. The blend contains CJC-1295 No DAC 5mg plus Ipamorelin 5mg; Tesamorelin is a distinct 44-amino-acid GHRH analog.

The bundle supports controlled comparison of GHRH-receptor and GHS-R1a signaling connected with the growth-hormone axis. It is not a protocol or an approved finished drug, and the separate vial format preserves the identity of each retail product.

How It Works

CJC-1295 No DAC activates GHRH receptors: The 29-residue analog supports study of cAMP-dependent pituitary signaling.

Ipamorelin activates GHS-R1a: The ghrelin-receptor pathway supplies a second upstream signal within the 10mg blend.

Tesamorelin provides a separate GHRH analog: Its 44-amino-acid structure supports comparison with the no-DAC CJC pathway in controlled models.

Analytical data

One certificate per vial

Independent third-party HPLC assesses each compound against its ≥99% purity target, while mass spectrometry confirms identity. For each vial, the results are documented in one combined, batch-specific COA report.

Lot: CJ-48928
Reported: 2026-05-12
Identity (LC-MS): Confirmed
Purity (HPLC-UV): 99.64%
Net content: 10.04 mg
Appearance: White lyophilized powder

Download COA

Lot: TE-32025
Reported: 2026-04-23
Identity (LC-MS): Confirmed
Purity (HPLC-UV): 99.46%
Net content: 10.00 mg
Appearance: White lyophilized powder

Download COA

Why Source from 321 Peptides?

Domestic accountability.

All included compounds are synthesized, manufactured, and finished in Certified GMP California and Arizona laboratory facilities—never sourced from overseas or Mexico. That means direct domestic supply-chain accountability from production through fulfillment.

Verification you can inspect.

Protected in transit.

Every included product is freeze-dried to help preserve stability during storage and shipping. Rapid domestic fulfillment reduces unnecessary time and handling.

Lot history 8 released lots

Every batch released under each vial in this bundle, with the figure reported for each. Vials are shipped from current stock.

Compound	Lot	Reported	Purity	Net content	COA
CJC-1295 No DAC + Ipamorelin 10mg	CJI433	2026-06-01	99.95%	Ipamorelin - 5.60 mg, CJC-1295 - 5.48 mg	PDF
	CJ-48928	2026-05-12	99.64%	10.04 mg	Pending
	CJ-49505	2026-04-30	99.88%	10.05 mg	Pending
	CJ-50082	2026-02-25	99.71%	10.06 mg	Pending
Tesamorelin 10mg	TE-32025	2026-04-23	99.46%	10.00 mg	Pending
	T522	2026-04-23	99.58%	9.85 mg	PDF
	TE-33179	2026-04-08	99.83%	10.02 mg	Pending
	TE-32602	2026-03-19	99.58%	10.01 mg	Pending

Frequently Asked Questions

What comes in the CJC-1295, Ipamorelin, and Tesamorelin bundle?

The bundle includes CJC-1295 No DAC + Ipamorelin 10mg (5mg + 5mg); Tesamorelin 10mg. Each retail product arrives in its original lyophilized vial with batch-specific COA documentation.

How do CJC-1295, Ipamorelin, and Tesamorelin differ?

CJC-1295 No DAC and Tesamorelin are structurally different GHRH-receptor analogs. Ipamorelin instead activates GHS-R1a, providing a distinct upstream research signal.